Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-03-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2025-019关于2024年度计提资产减值准备的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the 2024 annual asset impairment provision. It details the impairment testing, amounts, and accounting basis for various asset categories including accounts receivable, inventory, fixed assets, and goodwill. The announcement references the board meeting approval and audit committee opinions, and mentions that the impairment losses have been included in the 2024 annual consolidated financial report. The document is about the impairment provision for the fiscal year 2024 and includes detailed financial data and accounting policy references. It is not a full annual report but a specific financial disclosure related to asset impairment provisions. Given the detailed financial data and the nature of the disclosure, this fits best under Audit Report / Information (AR), which covers standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests excluding full annual reports. The document is not a report publication announcement since it contains substantive financial data and analysis, nor is it a regulatory filing or other category. Therefore, the classification is AR with high confidence. FY 2024
2025-03-28 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 9th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes approvals of various reports such as the 2024 President's Work Report, Board Work Report, Financial Statements, Profit Distribution Plan, Internal Control Self-Evaluation Report, and others. It also mentions that these reports will be submitted to the shareholders' meeting for approval and are published on designated websites and newspapers. The document is a formal board meeting resolution announcement, not the full annual report itself, nor is it a simple notice of report publication. It contains substantive content about board decisions and approvals related to the company's governance and financial matters. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-03-28 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company through a specific stock issuance in 2024. It includes specifics on the amount raised, fees, usage, cash management, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2024. It contains detailed financial figures and descriptions of fund usage, cash management agreements, and approvals by the board. This type of document corresponds to a Capital/Financing Update (CAP) as it focuses on fundraising, capital raised, and the use of those funds rather than a full annual report or audit report. It is not an announcement of a report publication but the report itself, given the length and detail. Therefore, the correct classification is CAP.
2025-03-28 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal control over financial reporting as of December 31, 2024. The content includes the auditor's responsibility, the company's responsibility, and an audit opinion on internal control effectiveness. There is no indication that this is a full annual report or interim financial report, but rather a standalone audit report focused on internal control. The document length is 5823 characters, which is sufficient to contain substantive audit content rather than just an announcement. Therefore, this document fits the category of an Audit Report / Information (AR). FY 2024
2025-03-28 Chinese
关于同一控制下企业合并追溯调整财务数据的议案
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from Jinling Pharmaceutical Co., Ltd. regarding retrospective adjustments to financial data due to a business combination under common control. It includes extensive financial tables showing adjustments to the consolidated balance sheet and income statement for prior periods. The content focuses on accounting treatment and restatement of financial figures due to a corporate restructuring event. This is not a full annual report but a specific audit-related disclosure about accounting adjustments and restatements. The document length is substantial (15,000 characters) and contains detailed financial data and explanations, indicating it is a standalone audit-related report rather than a brief announcement or a general regulatory filing. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2024
2025-03-28 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details amounts, dates, expected yields, and risk control measures related to cash management of idle raised funds. The document is a progress update on the use of raised funds for cash management, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion of results. It is not a regulatory certification or officer attestation. The document is longer than 5,000 characters and provides detailed information on cash management activities, which fits the category of Capital/Financing Update (CAP) as it relates to updates on company fundraising and capital usage activities. Therefore, the appropriate classification is CAP with high confidence.
2025-03-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.